The following is a list of what is included in the item above. Click the test(s) below to view what biomarkers are measured along with an explanation of what the biomarker is measuring.
Also known as: Microalbumin Random Urine with Creatinine
Also known as: C-Reactive Protein, CReactive Protein CRP, CRP
Also known as: CBC, CBC includes Differential and Platelets, CBC/PLT w/DIFF, Complete Blood Count (includes Differential and Platelets)
NOTE: Ulta Lab Tests provides CBC test results from Quest Diagnostics as they are reported. Often, different biomarker results are made available at different time intervals. When reporting the results, Ulta Lab Tests denotes those biomarkers not yet reported as 'pending' for every biomarker the test might report. Only biomarkers Quest Diagnostics observes are incorporated and represented in the final CBC test results provided by Ulta Lab Tests.
Also known as: Chem 12, Chemistry Panel, Chemistry Screen, CMP, Complete Metabolic Panel, Comprehensive Metabolic Panel CMP, SMA 12, SMA 20
Also known as: A1c, Glycated Hemoglobin, Glycohemoglobin, Glycosylated Hemoglobin, HA1c, HbA1c, Hemoglobin A1c, Hemoglobin A1c HgbA1C, Hgb A1c
Also known as: Insulin (fasting)
Also known as: Lipid Panel with Ratios (fasting), Lipid Profile with Ratios (fasting), Lipids
The Diabetes Management - Comprehensive panel contains 9 tests with 72 biomarkers.
Brief Description: The Diabetes Management - Comprehensive panel is an extensive diagnostic tool designed to provide a thorough evaluation of a patient's diabetic status and associated health risks. This panel includes a broad range of tests that assess blood glucose control, kidney function, lipid metabolism, inflammation, and overall metabolic health. By offering a detailed picture of a diabetic patient's condition, healthcare providers can develop and refine effective management and treatment plans to optimize patient outcomes and prevent complications.
Collection Method: Blood Draw and Urine Collection
Specimen Type: Whole Blood, Serum, and Urine
Test Preparation: Fasting for at least 12 hours is required.
The Diabetes Management - Comprehensive panel may be ordered for individuals who have been diagnosed with diabetes and require detailed monitoring to manage their condition effectively. It is also highly recommended for patients experiencing complications, those with uncontrolled diabetes, or individuals at high risk of developing diabetes. This panel is particularly useful for providing a comprehensive assessment that can guide treatment adjustments, monitor disease progression, and prevent complications.
The Diabetes Management - Comprehensive panel includes several critical tests that provide insights into various aspects of a patient's health:
Apolipoprotein A1 is the main protein component of HDL cholesterol, often referred to as "good" cholesterol. This test measures the levels of ApoA1 to assess the ability of HDL to remove cholesterol from arteries, thus providing insights into cardiovascular health.
Apolipoprotein B is the primary protein in LDL cholesterol and VLDL particles, known as "bad" cholesterol. High levels of ApoB indicate a higher number of atherogenic particles, which can contribute to plaque buildup in arteries and increase cardiovascular risk.
CRP is a marker of inflammation in the body. Elevated levels of CRP can indicate ongoing inflammation, which is a risk factor for cardiovascular diseases and can be associated with poor diabetes control.
Complete Blood Count with Differential and Platelets
This test evaluates the overall health of blood cells, including red blood cells, white blood cells, and platelets. It helps detect conditions such as anemia, infection, and other hematological disorders that can complicate diabetes management.
Comprehensive Metabolic Panel (CMP)
The CMP assesses various aspects of metabolic health, including kidney and liver function, electrolyte balance, and glucose levels. This test helps identify potential complications of diabetes, such as kidney damage and liver dysfunction.
Cystatin C is a marker for kidney function that provides a more sensitive assessment of glomerular filtration rate (GFR) than creatinine. Elevated levels can indicate early kidney disease, a common complication of diabetes.
Hemoglobin A1c (HbA1c) measures the average blood glucose concentration over the past two to three months. It is a key indicator of long-term glucose control and helps evaluate the effectiveness of a diabetes treatment plan.
The insulin test measures the level of insulin in the blood. It helps assess insulin production and resistance, providing insights into the patient’s metabolic health and guiding treatment adjustments.
This test measures total cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides. It provides ratios that help assess cardiovascular risk, which is crucial for managing diabetes-related cardiovascular complications.
Microalbumin, Random Urine with Creatinine
This test measures the amount of albumin in the urine, which can indicate early kidney damage. The inclusion of creatinine helps account for variations in urine concentration, providing a more accurate assessment of kidney health.
The Diabetes Management - Comprehensive panel is essential for detecting and monitoring various conditions associated with diabetes:
Diabetes Mellitus
This panel provides a comprehensive assessment of blood glucose control through Hemoglobin A1c and insulin levels, reflecting both long-term and immediate glucose management. These tests help diagnose diabetes, monitor the effectiveness of treatment, and guide adjustments to improve blood sugar control.
Diabetic Nephropathy
Microalbumin and Cystatin C tests are crucial for detecting early signs of kidney damage, a common complication of diabetes. Early detection allows for timely intervention to prevent progression, such as tighter blood pressure and glucose control, and potentially prescribing medications to reduce kidney strain.
Cardiovascular Disease
The Lipid Panel with Ratios, Apolipoprotein A1, Apolipoprotein B, and CRP tests help assess the risk of cardiovascular disease by measuring cholesterol levels, inflammation, and the balance of lipid particles. Diabetic patients are at a higher risk for heart disease, making these tests critical for managing their cardiovascular health.
Diabetes Mellitus
Healthcare professionals use Hemoglobin A1c and insulin results to evaluate how well a patient's blood glucose levels are controlled. This information guides adjustments in medication, diet, and lifestyle to improve glucose management and prevent complications.
Diabetic Nephropathy
Detecting microalbumin in the urine and elevated Cystatin C levels indicate early kidney damage. Physicians use these results to implement strategies to protect kidney function, such as tighter control of blood pressure and blood sugar levels, and possibly prescribing medications to reduce kidney strain.
Cardiovascular Disease
Lipid panel results, along with Apolipoprotein A1, Apolipoprotein B, and CRP levels, guide interventions to manage cholesterol levels and reduce cardiovascular risk. This may include lifestyle changes, dietary adjustments, and medications such as statins to lower LDL cholesterol and triglycerides while increasing HDL cholesterol.
The Diabetes Management - Comprehensive panel provides an extensive evaluation of essential health markers for individuals with diabetes. By assessing blood health, metabolic function, glucose control, kidney health, lipid metabolism, and inflammation, this panel offers valuable insights that help healthcare providers optimize treatment plans, detect complications early, and improve overall patient outcomes. Regular monitoring through this comprehensive panel supports proactive diabetes management and helps patients maintain better control over their health.